Pulmonology · Idiopathic Pulmonary FibrosisRegulatory Approvalcommercialnear-term

Aurobindo Pharma's Pirfenidone ANDA Submission Receives AP Status

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Aurobindo Pharma14 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/5/2026, 12:33:09 AM

Assessment confidence: 52% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.

Executive Thesis

Aurobindo Pharma's receipt of Abbreviated Approval (AP) for Pirfenidone signifies a new competitive entrant in the idiopathic pulmonary fibrosis market. This development necessitates a reassessment of market strategies by existing players to maintain their market share and pricing integrity. Regulatory context from FDA (FDA AP — PIRFENIDONE (ORIG)) supports the near-term read. Assessment grounded in 16 ranked evidence items (4 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of Aurobindo's entry on market share and pricing strategies for Pirfenidone. The strongest clinical anchor is A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis (ClinicalTrials.gov), sub-indication match (ild). In ild, 8 regulatory and 3 competitive items passed relevance filtering for Aurobindo Pharma.

Competitive Pressure

The most relevant competitive pressure comes from [Ad hoc announcement pursuant to Art. (Roche) — sponsor/company relevance (roche). Secondary pressure from Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217). This approval allows Aurobindo to enter the market for Pirfenidone, increasing competition against existing players in the idiopathic pulmonary fibrosis space.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — PIRFENIDONE (ORIG) (FDA). Entity match (aurobindo pharma); Regulatory pathway relevance (nda). The approval status indicates compliance with regulatory standards, but it does not imply immediate changes to existing product labels or approvals for other companies.

Key Opportunities

The entry of Aurobindo Pharma could lead to increased competition, potentially affecting pricing and market share for current products in the idiopathic pulmonary fibrosis space.
Upside for Aurobindo Pharma may improve if Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the impact of Aurobindo's entry on market share and pricing strategies for Pirfenidone.

What Would Change This Assessment

This becomes more urgent if Monitor for the launch timeline and any potential pricing strategies from Aurobindo Pharma.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — PIRFENIDONE (ORIG)
FDAmedium relevance
Entity match (aurobindo pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ICOSAPENT ETHYL (ORIG)
FDAmedium relevance
Entity match (aurobindo pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PREGABALIN (SUPPL)
FDAmedium relevance
Entity match (aurobindo pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ACETAMINOPHEN AND IBUPROFEN (SUPPL)
FDAmedium relevance
Entity match (aurobindo pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DIVALPROEX SODIUM (SUPPL)
FDAmedium relevance
Entity match (aurobindo pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAmedium relevance
Entity match (aurobindo pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
FDAmedium relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
FDAmedium relevance
Regulatory pathway relevance (nda)
FDA document
View source

A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
ClinicalTrials.govhigh relevance
Sub-indication match (ild)
FDA document
View source
Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis
ClinicalTrials.govhigh relevance
Sub-indication match (ild)
FDA document
View source
Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis
ClinicalTrials.govhigh relevance
Sub-indication match (ild)
FDA document
View source
19F MRI in Healthy Children and Children With Mild Cystic Fibrosis Lung Disease
ClinicalTrials.govmedium relevance
Sub-indication match (ild)
FDA document
View source
Feedback-Based Balance Training for Adolescents With Idiopathic Scoliosis
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Ultrasound-Guided Versus Standard Margin Selection in Ileocecal Resection of Terminal Ileal CD
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

[Ad hoc announcement pursuant to Art.
Rochemedium relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochemedium relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochemedium relevance
Sponsor/company relevance (Roche)
FDA document
View source
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalslow relevance
Sponsor/company relevance (Roche)
Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Humanexa Signalslow relevance
Sponsor/company relevance (Roche)

Association between smoking and prognosis in idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
PubMedhigh relevance
Sub-indication match (ild)
FDA document
View source
Insect-based models in pharmaceutical ecotoxicology: a bibliometric and narrative review.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Aurobindo Pharma
Pirfenidone

Commercial impact

medium

The entry of Aurobindo Pharma could lead to increased competition, potentially affecting pricing and market share for current products in the idiopathic pulmonary fibrosis space.

Regulatory impact

low

The approval status indicates compliance with regulatory standards, but it does not imply immediate changes to existing product labels or approvals for other companies.

What to watch

Monitor for the launch timeline and any potential pricing strategies from Aurobindo Pharma.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.